Get the Stockscreener App
2.20
2.33%
0.05
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.20, with a volume of 462.01K.
It is up +2.33% in the last 24 hours and down -14.73% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.15
Open:
$2.16
24h Volume:
462.01K
Relative Volume:
0.46
Market Cap:
$106.28M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.5942
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-5.98%
1M Performance:
-14.73%
6M Performance:
-13.73%
1Y Performance:
-92.63%
1-Day Range:
$2.1476
$2.23
1-Week Range:
$2.105
$2.39
52-Week Range:
$1.15
$33.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.20 | 109.66M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Published on: 2025-08-20 23:17:10 - beatles.ru
Chart Patterns Forming a Bullish Setup in Cassava Sciences Inc. Equity WarrantPortfolio Gains Summary & Real-Time Market Sentiment Alerts - mustnews.co.kr
Bullish Candlestick Pattern Forms in Cassava Sciences Inc. Equity WarrantEarnings Beat & Trade Opportunity Analysis - beatles.ru
How Cassava Sciences Inc. Equity Warrant stock performs during market volatilityPortfolio Value Report & Weekly High Conviction Ideas - beatles.ru
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences Advances Simufilam for Epilepsy Treatment - TipRanks
Published on: 2025-08-18 07:19:35 - sundaytimes.kr
Cassava Sciences Posts Q2 2025 Earnings: Mixed Results Amid Sector Stability - AInvest
Is It Too Late to Sell Cassava Sciences Inc. Equity WarrantGap Up & Target Return Focused Stock Picks - sundaytimes.kr
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA - ACCESS Newswire
Why Cassava Sciences Inc. Equity Warrant stock attracts strong analyst attentionJuly 2025 Fed Impact & Free Community Consensus Stock Picks - mustnews.co.kr
Cassava Sciences Posts Q2 Loss on Pivot - AOL.com
Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewswire
Elliott Wave Theory Predicts Pullback in Cassava Sciences Inc.2025 Trade Ideas & Daily Growth Stock Tips - thegnnews.com
Cassava Sciences reports Q2 EPS (92c) vs 13c last year - TipRanks
Is Cassava Sciences Inc. Starting a New Uptrend2025 Biggest Moves & Daily Profit Maximizing Trade Tips - thegnnews.com
CASSAVA SCIENCES INC SEC 10-Q Report - TradingView
Cassava Sciences Advances Simufilam Development for TSC-Related Epilepsy and Reports Financial Results for Q2 2025 - Quiver Quantitative
Why is Cassava Sciences Inc. Equity Warrant stock going downTop Earnings Growth Momentum Picks - thegnnews.com
Cassava Sciences Inc. Equity Warrant Stages Intraday Comeback — Trend ChangeValue Investing Picks With Stability Outlined - beatles.ru
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewswire
Cassava Sciences Boosts Medical Leadership with New CMO Appointment, Analysts Maintain Cautionary Price Target - AInvest
Cassava Sciences appoints Hulihan as Chief Medical Officer - TipRanks
Cassava Sciences appoints Dr. Joseph Hulihan as Chief Medical Officer - MarketScreener
Cassava Sciences' Strategic Hire of Joe Hulihan as CMO: A Catalyst for Accelerated Pipeline Development in Neurodegenerative Therapeutics - AInvest
Cassava Sciences appoints Joseph Hulihan as chief medical officer By Investing.com - Investing.com South Africa
Simufilam reduces tuberous sclerosis-associated seizures - BioWorld MedTech
Cassava Sciences Announces Positive Preclinical Results - TipRanks
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam For Tsc-Related Epilepsy - TradingView
SAVA’s simufilam cuts seizures in TSC mice; first human trial slated H1 2026 | SAVA SEC FilingForm 8-K - Stock Titan
Cassava Sciences Reports Positive Preclinical Results for Simufilam in Tuberous Sclerosis Complex-Related Epilepsy - Quiver Quantitative
Cassava Sciences and Simufilam: A Groundbreaking Opportunity in TSC-Related Epilepsy - AInvest
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - The Manila Times
What analysts say about Cassava Sciences Inc. Equity Warrant stockInvest like a pro with expert recommendations - Jammu Links News
What is the risk reward ratio of investing in Cassava Sciences Inc. stockTremendous growth opportunities - Jammu Links News
Why is Cassava Sciences Inc. stock attracting strong analyst attentionUncover the best stocks for explosive growth - Jammu Links News
Is Cassava Sciences Inc. stock overvalued or undervaluedMaximize your returns with portfolio optimization - Jammu Links News
What catalysts could drive Cassava Sciences Inc. stock higher in 2025Consistently high returns - Jammu Links News
Cassava Sciences Inc. Equity Warrant Stock Analysis and ForecastTremendous gains - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. stockPhenomenal capital gains - Jammu Links News
What are the technical indicators suggesting about Cassava Sciences Inc. Equity WarrantFree Trading Strategy Suggestions - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. Equity Warrant stockSuperior stock selection - Jammu Links News
Is Cassava Sciences Inc. Equity Warrant stock overvalued or undervaluedMaximize your portfolio’s growth potential - Jammu Links News
What is the dividend policy of Cassava Sciences Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
What makes Cassava Sciences Inc. Equity Warrant stock price move sharplyExponential wealth increase - Jammu Links News
How does Cassava Sciences Inc. compare to its industry peersHigh-profit stock alerts - Jammu Links News
How does Cassava Sciences Inc. generate profit in a changing economyExponentially increasing returns - Jammu Links News
Should I hold or sell Cassava Sciences Inc. Equity Warrant stock in 2025Maximize returns with smart investment plans - Jammu Links News
What drives Cassava Sciences Inc. Equity Warrant stock priceMarket-leading capital gains - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. in the next 12 monthsExceptional profit margins - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. Equity Warrant in the next 12 monthsCapitalize on emerging market opportunities - Jammu Links News
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):